1. Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus
   Camila Moreno Rosa et al, 2022, Antioxidants CrossRef
2. Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
   Tatsuhiko Urakami et al, 2023, Internal Medicine CrossRef
3. Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey
   Matthias Hepprich et al, 2023, BMJ Open Diabetes Research & Care CrossRef
4. DIABETIC NEPHROPATHY: NOVELTY ABOUT THE DIABETIC NEPHROPATHY TREATMENT IN CHILDREN
   Ievgeniia A. Burlaka et al, 2023, Wiadomości Lekarskie CrossRef
5. Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
   Khary Edwards et al, 2023, Therapeutic Advances in Endocrinology and Metabolism CrossRef
6. Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
   Abdulhalim M. Almurashi et al, 2023, Journal of the Indian Institute of Science CrossRef
7. Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes
   Mei-Ling Yang et al, 2022, Frontiers in Immunology CrossRef
8. The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
   Gabriella di Mauro et al, 2022, Pharmaceuticals CrossRef
9. The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
   Michail Koutentakis et al, 2023, Journal of Cardiovascular Development and Disease CrossRef
10. Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
    Laetitia Jacquot et al, 2023, Frontiers in Nephrology CrossRef
11. Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients
    Dong‐Dong Wang et al, 2022, Journal of Clinical Pharmacy and Therapeutics CrossRef
12. Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective
    Felix Aberer et al, 2022, Pharmaceutics CrossRef